Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 40

Sort by

Sort Order Select

Journal Articles

M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

Yoshimi Ohashi, Mutsumi Okamura, Asaka Hirosawa, Naomi Tamaki, Akinobu Akatsuka, Kuo-Ming Wu, Hyeong-Wook Choi, Kentaro Yoshimatsu, Isamu Shiina, Takao Yamori, Shingo Dan

Cancer Res (2016) 76 (13): 3895–3903.

https://doi.org/10.1158/0008-5472.CAN-15-2220

Published: 30 June 2016

View article titled, M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

Includes: Supplementary data

Journal Articles

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Oh-hara, Youngchul Song, Jeffrey A. Engelman, Naoya Fujita

Cancer Res (2013) 73 (10): 3087–3096.

https://doi.org/10.1158/0008-5472.CAN-12-3256

Published: 12 May 2013

View article titled, Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

Includes: Supplementary data

Journal Articles

Abstract 4450: Identification of IGF1R as a responsible factor and a therapeutic target for overcoming acquired and intrinsic resistance to PI3K inhibitors.

Shingo Dan, Sho Isoyama, Yumiko Nishimura, Naoki Nakamura, Gensei Kajiwara, Naomi Tamaki, Mutsumi Okamura, Takao Yamori

Cancer Res (2013) 73 (8_Supplement): 4450.

https://doi.org/10.1158/1538-7445.AM2013-4450

Published: 15 April 2013

View article titled, Abstract 4450: Identification of IGF1R as a responsible factor and a therapeutic target for overcoming acquired and intrinsic resistance to PI3K inhibitors.

Journal Articles

Abstract 4348: Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of tubulin polymerization in addition to c-Met inhibition.

Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Ohara, Youngchul Song, Jeffrey A. Engelman, Naoya Fujita

Cancer Res (2013) 73 (8_Supplement): 4348.

https://doi.org/10.1158/1538-7445.AM2013-4348

Published: 15 April 2013

View article titled, Abstract 4348: Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of tubulin polymerization in addition to c-Met inhibition.

Journal Articles

Abstract LB-357: Identification of a new inhibitor of the Golgi system, targeting ADP-ribosylation Factor 1 (Arf1) with potential for cancer therapy

Yoshimi Ohashi, Hiroshi Iijima, Noriyuki Yamaotsu, Kanami Yamazaki, Shigeo Sato, Mutsumi Okamura, Kenji Sugimoto, Shingo Dan, Shuichi Hirono, Takao Yamori

Cancer Res (2012) 72 (8_Supplement): LB-357.

https://doi.org/10.1158/1538-7445.AM2012-LB-357

Published: 15 April 2012

View article titled, Abstract LB-357: Identification of a new inhibitor of the Golgi system, targeting ADP-ribosylation Factor 1 (Arf1) with potential for cancer therapy

Journal Articles

Abstract 3302: The effects of the g-quadruplex ligand telomestatin to human brain tumor stem cell survival and growth

Takeshi Miyazaki, Yang Pan, Bin Hu, Habibe Demir, Kaushal Joshi, Sachiko Okabe, Takao Yamori, Mariano Viapiano, Kazuo Shin-ya, Hiroyuki Seimiya, Ichiro Nakano

Cancer Res (2011) 71 (8_Supplement): 3302.

https://doi.org/10.1158/1538-7445.AM2011-3302

Published: 15 April 2011

View article titled, Abstract 3302: The effects of the g-quadruplex ligand telomestatin to human brain tumor stem cell survival and growth

Journal Articles

Abstract 2655: Visualization of G1 arrest of cell cycle induced by inhibition of PI-3 kinase in cancer cells: in vitro evaluations

Yumiko Mukai, Shingo Dan, Mutsumi Okamura, Yasumichi Inoue, Aki Hanyu, Asako Sakaue-Sawano, Takeshi Imamura, Atsushi Miyawaki, Takao Yamori

Cancer Res (2011) 71 (8_Supplement): 2655.

https://doi.org/10.1158/1538-7445.AM2011-2655

Published: 15 April 2011

View article titled, Abstract 2655: Visualization of G1 arrest of cell cycle induced by inhibition of PI-3 kinase in cancer cells: in vitro evaluations

Journal Articles

Abstract 4399: In vitro and in vivo evaluations of correlation between the activation status of signaling pathways and the efficacy of anticancer compounds in a panel of JFCR39 human cancer cell lines

Shingo Dan, Mutsumi Okamura, Mariko Seki, Kanami Yamazaki, Yumiko Mukai, Takao Yamori

Cancer Res (2011) 71 (8_Supplement): 4399.

https://doi.org/10.1158/1538-7445.AM2011-4399

Published: 15 April 2011

View article titled, Abstract 4399: In vitro and in vivo evaluations of correlation between the activation status of signaling pathways and the efficacy of anticancer compounds in a panel of JFCR39 human cancer cell lines

Journal Articles

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations

Shingo Dan, Mutsumi Okamura, Mariko Seki, Kanami Yamazaki, Hironobu Sugita, Michiyo Okui, Yumiko Mukai, Hiroyuki Nishimura, Reimi Asaka, Kimie Nomura, Yuichi Ishikawa, Takao Yamori

Cancer Res (2010) 70 (12): 4982–4994.

https://doi.org/10.1158/0008-5472.CAN-09-4172

Published: 14 June 2010

View article titled, Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations

Includes: Supplementary data

Journal Articles

Abstract 2493: Inhibition of phosphoinositide 3-kinase suppressed growth of cancer cells with PIK3CA mutations or loss of PTEN expression via G₀/G₁ arrest of cell cycle but not apoptosis

Shingo Dan, Mutsumi Okamura, Hisashi Yoshimi, Yumiko Mukai, Kanami Yamazaki, Yasumichi Inoue, Aki Hanyu, Takeshi Imamura, Asako Sakaue-Sawano, Atsushi Miyawaki, Takao Yamori

Cancer Res (2010) 70 (8_Supplement): 2493.

https://doi.org/10.1158/1538-7445.AM10-2493

Published: 15 April 2010

View article titled, Abstract 2493: Inhibition of phosphoinositide 3-kinase suppressed growth of cancer cells with PIK3CA mutations or loss of PTEN expression via G0/G1 arrest of cell cycle but not apoptosis

Journal Articles

Abstract #LB-213: Evaluation of a PI3K inhibitor by an orthotopic brain tumor model

Takao Yamori, Mutsumi Okamura, Hisashi Yoshimi, Manabu Kawada, Takamitsu Fujimaki

Cancer Res (2009) 69 (9_Supplement): LB-213.

Published: 01 May 2009

View article titled, Abstract #LB-213: Evaluation of a PI3K inhibitor by an orthotopic brain tumor model

Journal Articles

Abstract #LB-214: Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels

Shingo Dan, Hironobu Sugita, Kanami Yamazaki, Takao Yamori

Cancer Res (2009) 69 (9_Supplement): LB-214.

Published: 01 May 2009

View article titled, Abstract #LB-214: Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels

Journal Articles

ZSTK474, a novel PI3K inhibitor, down-regulates CDC25A and induces G1 phase cell cycle arrest in human cancer cells

Shingo Dan, Yumiko Mukai, Shin-ichi Yaguchi, Takao Yamori

Cancer Res (2008) 68 (9_Supplement): 664.

Published: 01 May 2008

View article titled, ZSTK474, a novel PI3K inhibitor, down-regulates CDC25A and induces G1 phase cell cycle arrest in human cancer cells

Journal Articles

ZSTK474 is a specific class I PI3 kinase inhibitor

Dexin Kong, Shinichi Yaguchi, Takao Yamori

Cancer Res (2008) 68 (9_Supplement): 2307.

Published: 01 May 2008

View article titled, ZSTK474 is a specific class I PI3 kinase inhibitor

Journal Articles

Phosphoproteomic screening of biomarkers for assessing response to a PI3K inhibitor by using SELDI-TOF MS

Tetsuyuki Akashi, Shinichi Yaguchi, Mutsumi Okamura, Takao Yamori

Cancer Res (2008) 68 (9_Supplement): 2432.

Published: 01 May 2008

View article titled, Phosphoproteomic screening of biomarkers for assessing response to a PI3K inhibitor by using SELDI-TOF MS

Journal Articles

Epigenetic silencing of the RecQ helicase genes in Japanese lung cancer

Michiyo Okui, Yuichi Ishikawa, Takao Yamori, Ken Nakagawa

Cancer Res (2007) 67 (9_Supplement): 1927.

Published: 01 May 2007

View article titled, Epigenetic silencing of the RecQ helicase genes in Japanese lung cancer

Journal Articles

Proteomic screening for biomarkers for predicting sensitivity to anticancer drugs by using SELDI-TOF MS

Tetsuyuki Akashi, Yumiko Nishimura, Mieko Shiwa, Takao Yamori

Cancer Res (2007) 67 (9_Supplement): 2473.

Published: 01 May 2007

View article titled, Proteomic screening for biomarkers for predicting sensitivity to anticancer drugs by using SELDI-TOF MS

Journal Articles

EGFR signal pathways selectively activated in lung adenocarcinoma.

Miyako Hiramatsu, Hironori Ninomiya, Kentaro Inamura, Michiyo Okui, Yukitoshi Satoh, Mutsunori Fujiwara, Takao Yamori, Tomoyuki Kitagawa, Yuichi Ishikawa

Cancer Res (2007) 67 (9_Supplement): 5038.

Published: 01 May 2007

View article titled, EGFR signal pathways selectively activated in lung adenocarcinoma.

Journal Articles

Ectopic expression of PIK3CD in human cancer cell lines and human lung carcinoma

Hiroyuki Nakamura, Shingo Dan, Tetsuyuki Akashi, Michiyo Okui, Shinichi Egawa, Yuichi Ishikawa, Michiaki Unno, Takao Yamori

Cancer Res (2007) 67 (9_Supplement): LB-18.

Published: 01 May 2007

View article titled, Ectopic expression of PIK3CD in human cancer cell lines and human lung carcinoma

Journal Articles

Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

Bayasi Guleng, Keisuke Tateishi, Miki Ohta, Fumihiko Kanai, Amarsanaa Jazag, Hideaki Ijichi, Yasuo Tanaka, Miwa Washida, Keita Morikane, Yasushi Fukushima, Takao Yamori, Takashi Tsuruo, Takao Kawabe, Makoto Miyagishi, Kazunari Taira, Masataka Sata, Masao Omata

Cancer Res (2005) 65 (13): 5864–5871.

https://doi.org/10.1158/0008-5472.CAN-04-3833

Published: 01 July 2005

View article titled, Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

NARROW

M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

Abstract 4450: Identification of IGF1R as a responsible factor and a therapeutic target for overcoming acquired and intrinsic resistance to PI3K inhibitors.

Abstract 4348: Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of tubulin polymerization in addition to c-Met inhibition.

Abstract LB-357: Identification of a new inhibitor of the Golgi system, targeting ADP-ribosylation Factor 1 (Arf1) with potential for cancer therapy

Abstract 3302: The effects of the g-quadruplex ligand telomestatin to human brain tumor stem cell survival and growth

Abstract 2655: Visualization of G1 arrest of cell cycle induced by inhibition of PI-3 kinase in cancer cells: in vitro evaluations

Abstract 4399: In vitro and in vivo evaluations of correlation between the activation status of signaling pathways and the efficacy of anticancer compounds in a panel of JFCR39 human cancer cell lines

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations

Abstract 2493: Inhibition of phosphoinositide 3-kinase suppressed growth of cancer cells with PIK3CA mutations or loss of PTEN expression via G₀/G₁ arrest of cell cycle but not apoptosis

Abstract #LB-213: Evaluation of a PI3K inhibitor by an orthotopic brain tumor model

Abstract #LB-214: Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels

ZSTK474, a novel PI3K inhibitor, down-regulates CDC25A and induces G1 phase cell cycle arrest in human cancer cells

ZSTK474 is a specific class I PI3 kinase inhibitor

Phosphoproteomic screening of biomarkers for assessing response to a PI3K inhibitor by using SELDI-TOF MS

Epigenetic silencing of the RecQ helicase genes in Japanese lung cancer

Proteomic screening for biomarkers for predicting sensitivity to anticancer drugs by using SELDI-TOF MS

EGFR signal pathways selectively activated in lung adenocarcinoma.

Ectopic expression of PIK3CD in human cancer cell lines and human lung carcinoma

Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only